[go: up one dir, main page]

MX2016012623A - Combinacion de adapaleno y peroxido de benzoilo para tratar cicatrices de acne. - Google Patents

Combinacion de adapaleno y peroxido de benzoilo para tratar cicatrices de acne.

Info

Publication number
MX2016012623A
MX2016012623A MX2016012623A MX2016012623A MX2016012623A MX 2016012623 A MX2016012623 A MX 2016012623A MX 2016012623 A MX2016012623 A MX 2016012623A MX 2016012623 A MX2016012623 A MX 2016012623A MX 2016012623 A MX2016012623 A MX 2016012623A
Authority
MX
Mexico
Prior art keywords
adapalene
benzoyl peroxide
acne scars
combination
treating acne
Prior art date
Application number
MX2016012623A
Other languages
English (en)
Other versions
MX376949B (es
Inventor
BOURDES Valérie
Martel Philippe
Rivier Michel
Reynier Philippe
Petit Laurent
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52780548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016012623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of MX2016012623A publication Critical patent/MX2016012623A/es
Publication of MX376949B publication Critical patent/MX376949B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un método para tratar y/o prevenir las cicatrices de acné, en donde una cantidad efectiva de una composición que contiene una combinación fija de adapaleno o una sal del mismo y peróxido de benzoilo, es administrado a un paciente en necesidad de la misma. La presente invención se refiere además a una composición que contiene una combinación fija de adapaleno o una sal del mismo y peróxido de benzoilo, para su uso, para el tratamiento y/o prevención de cicatrices de acné.
MX2016012623A 2014-04-01 2015-03-30 Combinación de adapaleno y peróxido de benzoilo para tratar cicatrices de acné. MX376949B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973350P 2014-04-01 2014-04-01
PCT/EP2015/056906 WO2015150332A1 (en) 2014-04-01 2015-03-30 Combination of adapalene and benzoyl peroxide for treating acne scars

Publications (2)

Publication Number Publication Date
MX2016012623A true MX2016012623A (es) 2016-12-14
MX376949B MX376949B (es) 2025-03-07

Family

ID=52780548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012623A MX376949B (es) 2014-04-01 2015-03-30 Combinación de adapaleno y peróxido de benzoilo para tratar cicatrices de acné.

Country Status (11)

Country Link
US (1) US20170020833A1 (es)
EP (1) EP3125880B1 (es)
KR (2) KR20220148939A (es)
AU (1) AU2015239688B2 (es)
BR (1) BR112016022743A2 (es)
CA (1) CA2944073A1 (es)
CL (1) CL2016002489A1 (es)
MX (1) MX376949B (es)
RU (1) RU2016142678A (es)
SG (2) SG11201608222WA (es)
WO (1) WO2015150332A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037733A1 (en) * 2019-08-23 2021-03-04 Allergan Pharmaceuticals International Limited Tropoelastin for use in treatment of acne scarring
JPWO2023068233A1 (es) * 2021-10-18 2023-04-27

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833841B1 (fr) 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
FR2901139B1 (fr) * 2006-05-17 2009-03-20 Galderma Res & Dev S N C Snc Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations
US8080537B2 (en) * 2006-07-13 2011-12-20 Galderma Research & Development Combinations of adapalene and benzoyl peroxide for treating acne lesions
FR2903603B1 (fr) * 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
DK2114392T3 (en) * 2007-01-30 2015-09-07 Galderma Res & Dev Applied adapalene and benzoyl peroxide FOR LONG-TERM TREATMENT OF ACNE VULGARIS
WO2011098391A1 (en) * 2010-02-09 2011-08-18 Galderma Research & Development A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non- caucasian population with decrease of post- inflammatory hyperpigmentation
CA2796412A1 (en) * 2010-04-29 2011-11-03 Galderma Research & Development Method for treating scars with adapalene 0.3%
US20160310512A1 (en) * 2013-12-19 2016-10-27 Galderma Research & Development Therapy regimen for treating severe acne related diseases

Also Published As

Publication number Publication date
CL2016002489A1 (es) 2017-02-03
SG10202100745QA (en) 2021-02-25
US20170020833A1 (en) 2017-01-26
BR112016022743A2 (pt) 2017-08-15
KR20220148939A (ko) 2022-11-07
EP3125880B1 (en) 2019-11-20
WO2015150332A1 (en) 2015-10-08
KR20160130862A (ko) 2016-11-14
SG11201608222WA (en) 2016-10-28
RU2016142678A (ru) 2018-05-07
MX376949B (es) 2025-03-07
AU2015239688A1 (en) 2016-10-13
AU2015239688B2 (en) 2020-06-25
EP3125880A1 (en) 2017-02-08
CA2944073A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
CL2016002971A1 (es) Combinación.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
AR101740A1 (es) Terapia de combinación y composiciones
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
SV2017005444A (es) Método para tratar prevenir o reducir el riesgo de infección cutánea
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.

Legal Events

Date Code Title Description
FG Grant or registration